Company intelligence / Profile preview

Apozeal Pharmaceuticals Inc.

Ownership: Private
Development stage: Commercial

Overview

Apozeal Pharmaceuticals owns 10 FDA-approved ANDA products for the US market, with several more awaiting approval or in development. The company recently launched Hydroxyzine HCL Solution as its first marketed product from its Levittown, PA facility. Plans are underway to launch nine additional FDA-approved products soon. The company is focused on high-quality manufacturing of both branded and generic pharmaceuticals at affordable prices

Therapeutic areas: PsychiatryDermatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

hydroxyzine

Commercial

Indications: Anxiety, Psychoneurosis, Pruritus, Chronic urticaria, Atopic dermatitis, Contact dermatitis

Partnerships

Acquired Torrent Pharma's Levittown facility/products

Beyond the preview

Go deeper on Apozeal Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apozeal Pharmaceuticals Inc..

Explore the full profile